National University Corporation Tokyo Medical and Dental University Patent applications |
Patent application number | Title | Published |
20160130583 | DOUBLE-STRANDED ANTISENSE NUCLEIC ACID WITH EXON-SKIPPING EFFECT - Disclosed are double-stranded antisense nucleic acid complexes that can efficiently alter the processing of RNA in a cell via an antisense effect, and methods for using the same. One method comprises contacting with the cell a double-stranded nucleic acid complex comprising: a first nucleic acid strand annealed to a second nucleic acid strand, wherein: the first nucleic acid strand comprises (i) nucleotides independently selected from natural DNA nucleotides, modified DNA nucleotides, and nucleotide analogs, (ii) no regions that have 4 or more consecutive natural DNA nucleotides, (iii) the total number of natural DNA nucleotides, modified DNA nucleotides, and nucleotide analogs in the first nucleic acid strand is from 8 to 100, and (iv) the first nucleic acid strand is capable of hybridizing to RNA inside of the cell; and the second nucleic acid strand comprises nucleotides independently selected from natural RNA nucleotides, modified RNA nucleotides, and nucleotide analogs. | 05-12-2016 |
20160108395 | CHIMERIC SINGLE-STRANDED ANTISENSE POLYNUCLEOTIDES AND DOUBLE-STRANDED ANTISENSE AGENT - Chimeric single-stranded polynucleotides and double-stranded antisense agents useful for modifying the expression of a target gene by means of an antisense effect are disclosed. The chimeric single-stranded antisense polynucleotide and double-stranded antisense agents comprise a central nucleotide region flanked by a first 5′-wing region and a first 3′-wing region of modified nucleotides, which are themselves flanked by a second 5′-wing region and/or a second 3′-wing region of nucleotides that have a low affinity for proteins and/or that have higher resistance to DNase or RNase than a natural DNA or RNA and are missing in a cell when the chimeric polynucleotide delivered. The double-stranded antisense agent further comprises a complementary strand annealed to the antisense strand. The polynucleotide can be used to modify RNA transcription levels, miRNA activity, or protein levels in cells. | 04-21-2016 |
20160053257 | METHOD FOR ASSAYING MICRORNA, CANCER THERAPEUTIC AGENT, AND MEDICINAL COMPOSITION CONTAINING SAME FOR CANCER THERAPY - The present inventors have found microRNAs which are strongly associated with stabilization of NRF2 in tumors, and an object of the present invention is to provide means for utilizing such miRNAs for the diagnosis and treatment of cancer. The inventors conducted screening of 470 microRNAs in a microRNA library by use of HeLa cells. As a result, 8 miRNAs each exhibiting a large decrease in miRNA activity as compared with a control miRNA, and 8 miRNAs each exhibiting a large increase in miRNA activity as compared with a control miRNA, were identified. The inventors have found that the NRF2 activation in the living body, in particular tumor cells, can be detected by use of the thus-identified miRNAs, whereby malignancy of a tumor, or the like can be differentiated. The inventors have also found that a nucleic acid including a miRNA sequence associated with reduction in the aforementioned ARE activity can be used as a cancer therapeutic agent. | 02-25-2016 |
20150320350 | BRAIN FUNCTION EVALUATION SYSTEM AND BRAIN FUNCTION EVALUATION METHOD - In order to evaluate a motor-function disorder accompanying a brain disease by a non-conventional new method, a brain function evaluation system | 11-12-2015 |
20150225421 | COMPOUND AND PHARMACEUTICAL COMPOSITION FOR NEUROPSYCHOLOGICAL DISORDER OR MALIGNANT TUMOR - The present invention provides a compound and a pharmaceutical composition for neuropsychological disorders or malignant tumors, the use of the compound and the pharmaceutical composition, or a method for preventing, improving, inhibiting the development of, and/or treating neuropsychological disorders or malignant tumors with the use of the compound and the pharmaceutical composition. One or more embodiments disclose a compound expressed by the following general formula (I) or (II) or a pharmaceutically acceptable salt of the compound: | 08-13-2015 |
20150191484 | NOVEL COMPOUNDS HAVING A TETRACYCLIC IRIDOID SKELTON AND AN ANTI-TRYPANOSOMAL AGENT COMPRISING THE SAME AS AN ACTIVE INGREDIENT - The present invention provides anti-trypanosomal agent for treating, preventing Trypanosomiasis of mammals, which comprises a compound having the tetracyclic iridoid skeleton represented by a general formula (I). | 07-09-2015 |
20150056141 | BENZOTHIOPHENE COMPOUND, ALTERNATIVE AUTOPHAGY-INDUCING AGENT AND ANTICANCER AGENT INCLUDING THE COMPOUND AS ACTIVE INGREDIENT, AND METHOD FOR SCREENING FOR COMPOUND HAVING ANTICANCER ACTIVITY - It has been found that efficient screening for a compound having anticancer activity can be achieved by selecting a compound having activity to induce alternative autophagy using, as an index, formation of fluorescent bright spots due to aggregation of a lysosomal protein to which a fluorescent protein is attached in cells expressing the lysosomal protein. In addition, it has been found that a benzothiophene compound represented by the following general formula (1) has alternative autophagy-inducing activity and anticancer activity: | 02-26-2015 |
20150051347 | BLOCK COPOLYMER HAVING PHENYLBORONIC ACID GROUP INTRODUCED THEREIN, AND USE THEREOF - A block copolymer includes a polyamino acid chain segment and a hydrophilic polymer chain segment. The polyamino acid chain segment includes at least one amino acid residue having a side chain that contains a cationic group and at least one amino acid residue having a side chain that contains a substituted phenylboronic acid group. In the substituted phenylboronic acid group, at least one hydrogen of the phenyl ring is substituted so that the phenylboronic acid group has a pKa of less than 8. Such a block copolymer serves as a carrier that simultaneously imparts stability to a biotechnology-based drug in blood and provides suitable drug-releasing properties of the drug at an affected area. | 02-19-2015 |
20140370056 | Mucosal Vaccine Using Cationic Nanogel - A mucosal vaccine for the prevention or treatment of microbial infections is described that is capable of inducing vaccine antigen-specific immune responses in an organism without the addition of a mucosal adjuvant. The mucosal vaccine comprises a composite of a nanogel comprising a hydrophilic polysaccharide having a cationic functional group and a hydrophobic cholesterol added thereto as a side chain and a vaccine antigen. The vaccine is administered via a mucosal route. | 12-18-2014 |
20140343148 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR IDIOPATHIC INFLAMMATORY MYOPATHIES - Administration of isoleucine, leucine and valine is effective for the prophylaxis and/or therapy of idiopathic inflammatory myopathy or idiopathic inflammatory myopathy associated with steroid-induced myopathy that develops during the course of treatment. This method is effective for the prophylaxis and/or therapy of idiopathic inflammatory myopathy or idiopathic inflammatory myopathy associated with steroid-induced myopathy that develops during the course of treatment. | 11-20-2014 |
20140328808 | TECHNIQUE FOR ISOLATING/CULTURING COLORECTAL EPITHELIAL STEM CELL, AND TECHNIQUE FOR TRANSPLANTING COLORECTAL EPITHELIUM EMPLOYING SAID TECHNIQUE - It is an object of the present invention to provide a culture medium for in vitro culture of a colorectal epithelial stem cell or the like, a method of in vitro culturing a colorectal epithelial stem cell or the like using the culture medium, a prophylactic or therapeutic agent for a bowel disease containing a colorectal epithelial stem cell or the like cultured by the method, a method of administrating, i.e., transplanting a colorectal epithelial stem cell or the like cultured by the method to a bowel disease patient, and a method of isolating a colorectal epithelial stem cell or the like. The culture medium for in vitro culture of a colorectal epithelial stem cell and/or a colorectal epithelial cell characteristically contains serum albumin, Wnt3a, and r-spondin-1. | 11-06-2014 |
20140322344 | VACCINE PREPARATION FOR CANCER TREATMENT - A vaccine preparation for treating cancer includes a complex of a hydrophobized polysaccharide and at least one synthetic long peptide derived from a tumor-specific antigenic protein and/or a pathogen-derived antigenic protein. The at least one synthetic long peptide contains at least one CD8+ cytotoxic T-cell recognition epitope and at least one CD4+ helper T-cell recognition epitope. The complex is simultaneously administered to the patient with at least one immunopotentiating agent. | 10-30-2014 |
20140294971 | CANCER CELL-INHIBITING CERAMIC, PROCESS FOR PRODUCING CANCER CELL-INHIBITING CERAMIC, METHOD FOR TREATING BONE TUMOR, AND USE OF BETA-TRICALCIUM PHOSPHATE POROUS GRANULES WITH PARTICLE SIZE OF 1 TO 10 MICROMETER - Proliferation of cancer cells is effectively inhibited. Provided is a cancer cell-inhibiting ceramic containing a β-tricalcium phosphate porous granule with a particle size of 1 to 10 μm. The β-tricalcium phosphate porous granule is taken up into cancer cells at an affected area and have an effect of inhibiting proliferation of a cancer tissue. The β-tricalcium phosphate porous granule with a particle size of 1 to 10 μm can be used to more effectively inhibit the proliferation of the cancer cells. | 10-02-2014 |
20140271317 | BIOCOMPATIBLE Co-Cr-Mo ALLOY - The present invention is to provide a Co—Cr—Mo alloy excellent in mechanical properties such as yield strength and tensile strength. The present invention is a biocompatible Co—Cr—Mo alloy comprising, in mass %, more than 30% and not more than 36% of Cr, 5 to 8% of Mo, 0.20 to 0.65% of N, and the balance consisting of Co and inevitable impurities, and produced by layered manufacturing. The biocompatible Co—Cr—Mo alloy of the present invention preferably has a solidification structure of a dendrite structure and the primary arm spacing of the dendrite structure is not more than 5 μm. | 09-18-2014 |
20140248690 | LIQUID REFLUX HIGH-SPEED GENE AMPLIFICATION DEVICE - One embodiment provides a liquid reflux reaction control device comprising:
| 09-04-2014 |
20140206868 | PROCESS FOR PRODUCING v-COELENTERAZINE COMPOUNDS - A simple process for producing v-coelenterazine compounds has been desired. Described is a process for producing a v-coelenterazine compound represented by general formula (II) comprising (1) the step of reacting a compound of general formula (VIII) with a methyltriphenylphosphonium salt in the presence of a base to give a compound represented by general formula (IX), (2) the step of performing a ring-closing metathesis reaction on any one selected from the group consisting of the compound represented by general formula (IX) and a compound of general formula (X) which is the compound of general formula (IX) wherein the amino is protected with R | 07-24-2014 |
20140170331 | BIOMATERIAL, JOINT PROSTHESIS USING THE BIOMATERIAL AND METHOD OF PRODUCING THE SAME - The object of the present invention is to provide a joint prosthesis, bearing material and a production method thereof, which suppresses wear in a sliding section and suppresses the production of abrasive powder even during repeated daily operation. To achieve the object, there is provided a biomaterial comprising: a substrate made of metal, alloy or ceramic; and a biocompatible material layer laminated on the substrate, wherein hydroxyl groups are formed on the substrate by surface-treating, while the biocompatible material layer comprises a polymer containing phosphorylcholine groups, the substrate and the biocompatible material layer are bound via a binder layer which is combined with the hydroxyl groups of the substrate and with the biocompatible material layer. | 06-19-2014 |
20140120538 | COELENTERAZINE ANALOGUES AND COELENTERAMIDE ANALOGUES - Coelenterazine analogues with different luminescence properties from conventional ones and coelenteramide analogues with different fluorescence properties from conventional ones have been desired. The invention provides coelenterazine analogues modified at the 8-position of coelenterazine and coelenteramide analogues modified at the 2- or 3-position of coelenteramide. | 05-01-2014 |
20140056935 | PEPTIDE WHICH CAN INDUCE ANTIBODY CAPABLE OF RECOGNIZING STEREOSTRUCTURE OF HIV - An object of the present invention is to provide a peptide capable of inducing a superior or new neutralizing antibody against HIV, so that HIV infectious disease can be prevented and treated or a greater variety of preventive or therapeutic options can be offered. This object is achieved by using a peptide inducing an HIV's three-dimensional structure-recognizing antibody that recognizes a trimer region of C34, wherein three molecules of a derivative of a helical region C34 peptide at C-terminal region of transmembrane protein gp41 of an HIV particle are ligated via a C3-symmetric template compound having three equivalent linker structures. | 02-27-2014 |
20130314526 | CELL ANALYSIS DEVICE - Provided is a cell concentration/purification device having a function of successively locating cells in a specific area of a microchannel, and a function of sequentially capturing cell images by use of light from a plurality of monochromatic light sources on an image basis, and performing comparative analysis of the cell images to recognize individual cells based on information on the shape of the cells and an absorption spectral distribution of the cells or inside of the cells, thereby selectively separating/purifying the cells. | 11-28-2013 |
20130230881 | METHOD AND APPARATUS FOR TESTING CARDIOTOXICITY AND EVALUATING CARDIOMYOCYTES - In the present invention, a cardiomyocyte cluster is disposed on a transparent substrate, and the quality of the cardiomyocytes is evaluated from the response of the cells to a forced pulsation stimulus applied to the cardiomyocytes. The cardiomyocyte cluster is disposed on the transparent substrate, and is exposed to the flow of a liquid containing an agent in a manner so that the agent acts on the cells, which configure a network. The extent of cardiac toxicity resulting from the agent is evaluated from measuring the fluctuations obtained from a comparison of adjacent cardiomyocytes of the network. | 09-05-2013 |
20130116306 | SYSTEM FOR DELIVERING NUCLEIC ACIDS FOR SUPPRESSING TARGET GENE EXPRESSION BY UTILIZING ENDOGENOUS CHYLOMICRON - The object of present invention is to provide a system that can deliver in vivo nucleic acids such as an siRNA for suppressing a target gene expression in vivo more safely and efficiently, and to provide an expression-suppressing agent and a pharmaceutical composition utilizing the system. An introduction substance into chylomiclon, particularly nucleic acids to which an alpha-tocopherol is bound for suppressing a target gene expression, can be delivered more safely and efficiently into hepatic cells in vivo by administering the nucleic aids under the condition where the production of chylomicron is induced in the body. Alternatively, alpha-tocopherol-bound nucleic acids are mixed with extracted chylomiclon, and then they are administered. Consequently, a target gene expression is suppressed, thereby a disease caused by an elevated expression of the target gene can be treated more safely and efficiently. | 05-09-2013 |
20130101778 | BLOCK BODY FOR PRODUCING DENTURE BASE - To provide a most suitable block body for producing a denture base used when producing a denture base by cutting, the block body for producing a denture base is produced by polymerizing a (meth)acrylate monomer so as to have a color tone within a range that L* is 40 to 55, a* is 14 to 31, and b* is 5 to 20 when the color tone is measured with a sample thickness of 4 mm based on JIS Z8729, and to be preferably in a cylindrical shape having a diameter of 8 to 15 cm and a height of 1.5 to 5 cm, or in an elliptical-cylindrical shape having a major diameter and minor diameter of 8 to 15 cm and a height of 1.5 to 5 cm. | 04-25-2013 |
20130045479 | METHODS FOR EVALUATING THE STAGE OF OVARIAN CANCER OR THE SURVIVAL RATE OF AN OVARIAN CANCER PATIENT - An object of the present invention is to provide a method for detecting cancer through identification of genes exhibiting characteristic behavior in the cases of cancer such as ovarian cancer, and a cell growth inhibitor. The present invention provides a method for detecting cancer, which comprises detecting canceration including malignancy of a specimen through detection of at least one alteration of a gene existing in a chromosomal region 2q14. 2, 3p24. 1, 3q26. 2, 3q29, 4q34. 2, 6q23, 9p21. 3, 11q13. 3, 13q22.1, 13q33. 1, 13q33. 3, 15q12, 15q15. 1, 17p12, 17p13. 1, 17p13. 3, 18q21. 1, 18q21. 2, 18q21. 31, 18q21. 32, 18q21. 33, 18q23, 20q13. 13, 20q13. 2, 20q13. 31, 20q13. 33, Xp11. 23, Xp13.1, Xp13. 3, Xp26. 2, Xp26. 3, or Xq28 in the specimen. | 02-21-2013 |
20130029407 | CELL ANALYZER - Provided is a cell concentration and purification device, having: a function of continuously concentrating cells; a function of then subsequently disposing the cells continuously in a specific region of a channel; a function of simultaneously recognizing, based on an image, the shape and fluorescence emission of each single cell; and a function of recognizing the cells and then separating and purifying the same based on the data relating to the shape and fluorescence emission thereof. | 01-31-2013 |
20120232272 | PROCESS FOR PRODUCING v-COELENTERAZINE COMPOUNDS - A simple process for producing v-coelenterazine compounds has been desired. Described is a process for producing a v-coelenterazine compound represented by general formula (II) comprising (1) the step of reacting a compound of general formula (VIII) with a methyltriphenylphosphonium salt in the presence of a base to give a compound represented by general formula (IX), (2) the step of performing a ring-closing metathesis reaction on any one selected from the group consisting of the compound represented by general formula (IX) and a compound of general formula (X) which is the compound of general formula (IX) wherein the amino is protected with R | 09-13-2012 |
20120118292 | Artificial Respirator and Operation Method Thereof - To provide a compact and low-power-consumption artificial respirator and an operation method therefore including a controller which alternately switches between a first state for feeding inspiratory air stored in the reservoir tank to a patient and a second state for releasing expired air of the patient. A pressurizing pump has a discharge function for reversing a reduction of pressure within the reservoir tank, which is caused due to the inspiration, within an expiration period of time. | 05-17-2012 |
20110275109 | Immunity Evaluation Method, Apparatus and Program - An immunity evaluation method, apparatus, and program are provided that can evaluate comprehensive immunity with high precision. An immunity evaluation method for evaluating immunity from collected blood includes measuring a number of specific T cells that are CD8 positive and CD28 positive or negative in the collected blood, and determining a T lymphocyte age based on a regression equation on the basis of a correlation between a specific parameter that is dependent on the number of the specific T cells and age, and the number of specific T cells thus measured. | 11-10-2011 |
20110244481 | COELENTERAZINE ANALOGUES AND COELENTERAMIDE ANALOGUES - Coelenterazine analogues with different luminescence properties from conventional ones and coelenteramide analogues with different fluorescence properties from conventional ones have been desired. The invention provides coelenterazine analogues modified at the 8-position of coelenterazine and coelenteramide analogues modified at the 2- or 3-position of coelenteramide. | 10-06-2011 |
20110242485 | FLUORESCENCE IMAGE ACQUISITION METHOD, FLUORESCENCE IMAGE ACQUISITION PROGRAM, AND FLUORESCENCE IMAGE ACQUISITION APPARATUS - A fluorescence image acquisition method including: irradiating an eyeground with a short-pulse beam of light for exciting a fluorescent dye; setting the time point of emission of the light as a reference, measuring the intensities of luminescence of the fluorescent dye at two different times which are predetermined periods of time after the reference, determining the ratio between the intensities of luminescence at the two different times, and detecting the intensity of luminescence of the fluorescent dye having marked a target by using the ratio; and generating a fluorescence image of the fluorescent dye having marked the target, based on the results of detection by the detecting step. | 10-06-2011 |
20110165173 | THERAPEUTIC AGENT AND DETECTION REAGENT FOR ARTERIOSCLEROTIC DISEASE WHICH TARGETS FOR SALUSIN - The present invention provides a prophylactic and therapeutic agent for arteriosclerotic diseases and a method or reagent for detecting arteriosclerotic diseases. Further, the present invention provides a therapeutic agent for an arteriosclerotic disease, comprising salusin-α as an active ingredient, a therapeutic agent for an arteriosclerotic disease, comprising an antagonist of salusin-β as an active ingredient, and a method for detecting an arteriosclerotic disease, comprising assaying salusin-α in a biological sample. | 07-07-2011 |
20110151485 | METHOD FOR SCREENING FOR ANTIANGIOGENIC AGENT, AND METHOD FOR SCREENING FOR ANTIANGIOGENIC SIGNAL GENE - Disclosed are a method for screening for an antiangiogenic agent and a method for screening for an antiangiogenic gene, both of which are achieved by detecting an antiangiogenic signal within a short time by a simple means. The method for screening for an antiangiogenic agent comprises: a candidate compound administration step of administering a candidate compound for the antiangiogenic agent to a vascular endothelial cell or a cultured cell derived from a vascular endothelial cell; a cell-maintaining step of maintaining the vascular endothelial cell or the cultured cell derived from the vascular endothelial cell to which the candidate compound has been administered; and a signal detection step of detecting the phosphorylation of a protein phosphorylated by the administration of endostatin. | 06-23-2011 |
20100329971 | NOVEL HYDROXY RADICAL GENERATION METHOD, AND ANTI-VIRAL MATERIAL UTILIZING HYDROXYL RADICAL GENERATED BY THE METHOD - Disclosed is a novel hydroxy radical generation method which relies on a novel scientific fact relating to the generation of a hydroxy radical and the inactivation of a virus. Also disclosed is an anti-viral material produced by utilizing the method. The anti-viral material comprises a metal oxide powder and a hydroxide which enable the generation of a hydroxy radical that can inactivate a virus. An virus can be inactivated by the action of the hydroxy radical generated from the anti-viral material. | 12-30-2010 |
20100304997 | METHOD FOR DETECTING ABNORMAL SPOTS OF NUCLEIC ACID MICROARRAY - A method carries out a nucleic acid analysis using a nucleic acid microarray. A probe nucleic acid including a probe sequence (a′) complementary to a target sequence (a) and a sequence (b′) which is different from the probe sequence (a′) is immobilized on the nucleic acid microarray. The method includes hybridizing the nucleic acid microarray and a labeled abnormality detecting nucleic acid (B) containing a sequence (b) which can be bound to the sequence (b′), obtaining a labeled amount value (Fc1) of the labeled abnormality detecting nucleic acid (B) from a spot (X1), and determining, based on the measured labeled amount value (Fc1), as to whether or not the spot (X1) is an abnormal spot unsuitable for detecting the target nucleic acid. | 12-02-2010 |
20100262237 | Biomaterial, Joint Prosthesis Using the Biomaterial and Method of Producing the Same - The object of the present invention is to provide a joint prosthesis, bearing material and a production method thereof, which suppresses wear in a sliding section and suppresses the production of abrasive powder even during repeated daily operation. To achieve the object, there is provided a biomaterial comprising: a substrate made of metal, alloy or ceramic; and a biocompatible material layer laminated on the substrate, wherein hydroxyl groups are formed on the substrate by surface-treating, while the biocompatible material layer comprises a polymer containing phosphorylcholine groups, the substrate and the biocompatible material layer are bound via a binder layer which is combined with the hydroxyl groups of the substrate and with the biocompatible material layer. | 10-14-2010 |
20100234282 | SYSTEM FOR DELIVERING NUCLEIC ACIDS FOR SUPPRESSING TARGET GENE EXPRESSION BY UTILIZING ENDOGENOUS CHYLOMICRON - The object of present invention is to provide a system that can deliver in vivo nucleic acids such as an siRNA for suppressing a target gene expression in vivo more safely and efficiently, and to provide an expression-suppressing agent and a pharmaceutical composition utilizing the system. An introduction substance into chylomiclon, particularly nucleic acids to which an alpha-tocopherol is bound for suppressing a target gene expression, can be delivered more safely and efficiently into hepatic cells in vivo by administering the nucleic aids under the condition where the production of chylomicron is induced in the body. Alternatively, alpha-tocopherol-bound nucleic acids are mixed with extracted chylomiclon, and then they are administered. Consequently, a target gene expression is suppressed, thereby a disease caused by an elevated expression of the target gene can be treated more safely and efficiently. | 09-16-2010 |
20100178692 | MODEL CELL CHIP, APPARATUS FOR EVALUATING DRUG EFFECT USING THE MODEL CELL CHIP AND METHOD OF EVALUATING DRUG EFFECT - The present invention provides an apparatus for evaluating a drug effect enabling on-chip evaluation of the effect of a drug while the drug is acting on hERG-expressing cells. The present invention also provides a myocardial toxicity test apparatus and method therefor enabling in vitro myocardial toxicity testing that has previously been performed in vivo. | 07-15-2010 |
20100114321 | HOMUNCULUS - The object of the present invention is to provide a homunculus of a glenohumeral joint in which the supraspinatus and the infraspinatus are correctly connected to the superior humerus. A homunculus | 05-06-2010 |
20100113878 | Endoscopic multi-purpose treatment hood and endoscope - On the periphery of a silicon tube | 05-06-2010 |
20100099702 | Therapeutic agent for neuropathic pain - Disclosed is a therapeutic agent for neuropathic pain having an excellent therapeutic effect on neuropathic pain which is a intractable disease. More specifically, disclosed are a therapeutic agent for neuropathic pain which comprises a peripheral benzodiazepine receptor antagonist (particularly PK 11195) as the active ingredient; a pharmaceutical composition for the treatment of neuropathic pain which comprises a peripheral benzodiazepine receptor antagonist as the active ingredient; a method for the treatment of neuropathic pain using a peripheral benzodiazepine receptor antagonist; and others. | 04-22-2010 |
20100062978 | METHOD FOR INHIBITING SIGNAL TRANSDUCTION, SIGNAL TRANSDUCTION INHIBITOR TO BE USED THEREIN AND USE THEREOF - An object of the present invention is to provide a method for inhibiting activation of signaling pathway mediated by erbB1 or erbB2 in human cell and a signaling inhibitor to be used therefor. The above-described activation of signaling pathway can be inhibited by a polypeptide comprising at least one of PTB domain or ERK2 binding domain of human FRS2β. The above-described polypeptide may be introduced directly into cell, or nucleic acid which encodes for the above-described polypeptide may be introduced into cell to allow expression of the polypeptide in the cell. Such polypeptide and nucleic acid can be used, for example, as a signaling inhibitor. In addition, since erbB1 and erbB2 are involved in development of cancer, the above-described signaling inhibitor is also useful, for example, as an anticancer drug. | 03-11-2010 |
20090158448 | DNA ENCODING POLYPEPTIDE CAPABLE OF MODULATING MUSCLE-SPECIFIC TYROSINE KINASE ACTIVITY - Disclosed are DNA encoding a polypeptide which can modulate the activity of a muscle-specific tyrosine kinase, and others. The DNA is selected from the following members (a) to (d): (a) DNA comprising a specific nucleotide sequence; (b) DNA comprising a nucleotide sequence capable of hybridizing with a specific nucleotide sequence under stringent conditions; (c) DNA comprising a nucleotide sequence encoding an amino acid sequence having the substitution, deletion and/or addition of one or several amino acid residues in a specific amino acid sequence; and (d) DNA comprising a nucleotide sequence having 90% or higher homology to a specific nucleotide sequence. | 06-18-2009 |
20090118625 | Method for Measuring Flow Rate and Head of Centrifugal Pump, Apparatus Thereof, and Apparatus for Evaluating Circulatory State of Pulsating Cardiovascular System - In centrifugal pumps | 05-07-2009 |
20080279918 | Liposome And Method For Injecting Substance To Cell Using This Liposome - It is intended to efficiently inject into a target cell, a substance charged within a liposome. The present inventors have found that connexin synthesized within a liposome is introduced as connexon having a gap junction function into the liposome membrane. Specifically, the liposome according to the present invention is a liposome in which connexon composed of connexin synthesized by an in-vitro protein synthesis system is incorporated in a state of having a gap junction function. | 11-13-2008 |
20080220089 | Medical agent for preventing or treating diseases resulting from one of inflammation and remodeling, and method for preventing or treating the diseases - An object of the present invention is to provide a medical agent that has an excellent effect on the diseases resulting from one of inflammation and remodeling and that can prevent or treat them in response to various mechanisms of onset and development of the diseases. Thus, the present invention relates to a medical agent for preventing or treating diseases resulting from one of inflammation and remodeling in blood vessel, including nanobubbles. | 09-11-2008 |